The EPS decline has disappointed the market, leaving investors hesitant to buy. Shareholders face a total loss of 3% per year over five years due to the company's poor performance.
Despite a recent earnings dip, Jafron Biomedical's high P/E ratio is justified by its promising earnings outlook. Investors anticipate robust future growth, outweighing any potential earnings deterioration.